These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17550961)

  • 1. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model.
    Yeung SC; She M; Yang H; Pan J; Sun L; Chaplin D
    J Clin Endocrinol Metab; 2007 Aug; 92(8):2902-9. PubMed ID: 17550961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors.
    Dziba JM; Marcinek R; Venkataraman G; Robinson JA; Ain KB
    Thyroid; 2002 Dec; 12(12):1063-70. PubMed ID: 12593719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.
    Yeung SC; Xu G; Pan J; Christgen M; Bamiagis A
    Cancer Res; 2000 Feb; 60(3):650-6. PubMed ID: 10676649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma.
    Xu G; Pan J; Martin C; Yeung SC
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1769-77. PubMed ID: 11297616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model.
    She M; Jim Yeung SC
    Cancer Lett; 2006 Jul; 238(2):197-201. PubMed ID: 16154259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma.
    Prichard CN; Kim S; Yazici YD; Doan DD; Jasser SA; Mandal M; Myers JN
    Laryngoscope; 2007 Apr; 117(4):674-9. PubMed ID: 17429874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel.
    Pan J; Xu G; Yeung SC
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4731-40. PubMed ID: 11600533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of parathyroid hormone-related protein levels (PTHrP) in anaplastic thyroid cancer.
    Dackiw A; Pan J; Xu G; Yeung SC
    Surgery; 2005 Sep; 138(3):456-63. PubMed ID: 16213899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-2-associated X protein is the main mediator of manumycin a-induced apoptosis in anaplastic thyroid cancer cells.
    Pan J; Huang H; Sun L; Fang B; Yeung SC
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3583-91. PubMed ID: 15769983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Kim S; Prichard CN; Younes MN; Yazici YD; Jasser SA; Bekele BN; Myers JN
    Clin Cancer Res; 2006 Jan; 12(2):600-7. PubMed ID: 16428506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.
    Gomez-Rivera F; Santillan-Gomez AA; Younes MN; Kim S; Fooshee D; Zhao M; Jasser SA; Myers JN
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4519-27. PubMed ID: 17671138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate.
    Gao M; Zhang D; Yao N; Jin Q; Jiang C; Zhang J; Wang F
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1187-1194. PubMed ID: 31520101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
    Gao M; Zhang D; Jin Q; Jiang C; Wang C; Li J; Peng F; Huang D; Zhang J; Song S
    Oncotarget; 2016 Sep; 7(36):58133-58141. PubMed ID: 27531898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-Encapsulation of Combretastatin-A4 Phosphate and Doxorubicin in Polymersomes for Synergistic Therapy of Nasopharyngeal Epidermal Carcinoma.
    Zhu J; Xu X; Hu M; Qiu L
    J Biomed Nanotechnol; 2015 Jun; 11(6):997-1006. PubMed ID: 26353589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11.
    Kim S; Yazici YD; Barber SE; Jasser SA; Mandal M; Bekele BN; Myers JN
    Head Neck; 2006 May; 28(5):389-99. PubMed ID: 16388530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.
    Copland JA; Marlow LA; Kurakata S; Fujiwara K; Wong AK; Kreinest PA; Williams SF; Haugen BR; Klopper JP; Smallridge RC
    Oncogene; 2006 Apr; 25(16):2304-17. PubMed ID: 16331265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
    Schiff BA; McMurphy AB; Jasser SA; Younes MN; Doan D; Yigitbasi OG; Kim S; Zhou G; Mandal M; Bekele BN; Holsinger FC; Sherman SI; Yeung SC; El-Naggar AK; Myers JN
    Clin Cancer Res; 2004 Dec; 10(24):8594-602. PubMed ID: 15623643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
    Rustin GJ; Shreeves G; Nathan PD; Gaya A; Ganesan TS; Wang D; Boxall J; Poupard L; Chaplin DJ; Stratford MR; Balkissoon J; Zweifel M
    Br J Cancer; 2010 Apr; 102(9):1355-60. PubMed ID: 20389300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.